Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.

Gilead Sciences

Leerink Partners

Decheng Capital

Biotechnology Value Fund

Droia Ventures

Celgene

Aisling Capital

Taiho Ventures

The Column Group

Arcus Biosciences

HSTS

DNSSEC

reCAPTCHA

IPv6

Person Schema

Gravatar Profiles

Apple Mobile Web App Capable

reCAPTCHA v2

HSTS IncludeSubdomains PreLoad

Microsoft

Chief Financial Officer

Bob Goeltz

Broker/Owner

Donald Seitz

Chief Commercial Officer

Eric Matthews

Chief Operating Officer

Jennifer Jarrett

President, Co-Founder, Board of Directors

Juan Carlos Jaen

Board Member, Nominating & Governance Committee

Nicole Lambert

Terry Rosen

Vice President, Clinical Operations

Aimee Rieger

Vice President, Preclinical and Small Molecule Pharmaceutical Development (CMC)

Andrew Pennell

Vice President, Intellectual Property

Briana Barron

Yasunori Kaneko

Blake Byers

Kathryn E. Falberg

Juan Jaen

David Beier

Johanna Mercier

William Grossman

Chief Medical Officer

Nick Giafis

Vice President and Head of Medical Affairs

Patricia Carlos

VP of Regulatory Affairs

Katherine Bock

VP of Investor Relations and Corporate Strategy

Steve Young

SVP of Technology and Quantitative Biology

Nigel Walker

SVP of Protein Therapeutics

President & Co-Founder

Pharmaceutical Public Companies With Fewer Than 1000 Employees

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

California Companies With More Than $1M in Revenue (Top 10K)

San Francisco Bay Area Companies With More Than $1M in Revenue (Top 10K)

Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.

It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio.

Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.

Hercules Capital

Post-IPO Debt - Arcus Biosciences

Post-IPO Equity - Arcus Biosciences

Google Ventures

Series C - Arcus Biosciences

Series B - Arcus Biosciences

Series A - Arcus Biosciences

Computer and Software Services and Scientific Services

Hayward

California

United States

North America

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences falls -9.3%

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Arcus Biosciences describes discovery, discloses structure of AB-521

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

An investigational Fc-silent monoclonal antibody that targets TIGIT to potentially activate the immune system against cancer cells.

An investigational monoclonal antibody that binds to PD-1, potentially restoring the antitumor activity of T cells.

An investigational small molecule that acts as a dual A2a/A2b adenosine receptor antagonist.

An investigational small molecule that inhibits CD73, potentially reducing immunosuppression in tumors.

An investigational small molecule inhibitor of HIF-2⍺, which may have antitumor activity in renal cell cancer.

An investigational humanized Fc-silent IgG1 anti-CD39 antibody that may promote anti-tumor immunity.

South Korea

Asia

Lithuania

Europe

France

Bangladesh

HTML5

Comodo PositiveSSL Certificates

GoDaddy Premium DNS

Apache Server

Amazon Route 53

jQuery

Amazon EC2

Adobe Fonts

GoDaddy

Google Tag Manager

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

news impact assignment basic	general
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	cac60bf4
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	9e204494
crunchbase profile	general	Nov 22, 2024 8:45 AM	1fcdcb65
li profile	general	Jan 26, 2024 11:03 PM	f495618c
translate crunchbase fundingrounds	general	Nov 22, 2024 10:57 AM	ed45a668
peers	general
news basic	general	Dec 4, 2024 2:13 PM	27971631
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ARCUSBIO

Arcus Biosciences

Last Close

14.28

22/11 21:00

Market Cap

1.27B

Beta: -

Volume Today

534.33K

Avg: -